SCHEMBL2102887

SCHEMBL2102887

CC(Sc1ccccc1O)C(=O)c1ccc(O[Si](C(C)C)(C(C)C)C(C)C)cc1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 1/20 0.36
ADORA1 P30542 1/20 0.36
SMN1; SMN2 Q16637 2/20 0.34
OPRM1 P35372 1/20 0.33
OPRL1 P41146 1/20 0.33
CA12 O43570 1/20 0.32
CA1 P00915 1/20 0.32
CA2 P00918 1/20 0.32
CA7 P43166 1/20 0.32
CA9 Q16790 1/20 0.32
CA14 Q9ULX7 1/20 0.32
NPC1 O15118 3/20 0.32
RAB9A P51151 2/20 0.32
ATM Q13315 1/20 0.32
ELANE P08246 1/20 0.31
CYP1A2 P05177 1/20 0.31
CYP3A4 P08684 1/20 0.31
CYP2D6 P10635 1/20 0.31
CYP2C9 P11712 1/20 0.31
CYP2C19 P33261 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2101678 0.85 ALDH1A1 (0.41) SMN1; SMN2OPRM1OPRL1NPC1RAB9A
SCHEMBL2100073 0.85 POLB (0.38) SMN1; SMN2NPC1RAB9AATMP4HB
SCHEMBL2102383 0.79 RAB9A (0.49) SMN1; SMN2NPC1RAB9APOLBKMT2A
SCHEMBL2099236 0.79 CNR1 (0.35) OPRM1CYP3A4CYP2C9P4HBMEN1
SCHEMBL4703946 0.76 P4HB (0.41) SMN1; SMN2CYP2D6CYP2C9CYP2C19P4HB
SCHEMBL2103658 0.75 NPY5R (0.32) NPY5RP4HBALDH1A1
SCHEMBL2099038 0.71 ALDH1A1 (0.42) SMN1; SMN2RAB9AATMELANECYP1A2
SCHEMBL17070018 0.71 ELANE (0.58) SMN1; SMN2NPC1RAB9AELANENPSR1
SCHEMBL2099208 0.70 CES2 (0.42) SMN1; SMN2NPC1RAB9AELANECYP1A2
SCHEMBL2163425 0.69 KMT2A (0.58) SMN1; SMN2CA1CA2KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8163770-B2 Benzoxathiin derivative MSD. K. K. (JP) 2012-04-24 US disclosed
US-20100168156-A1 Novel Benzoxathiine Derivative BANYU PHARMACEUTICAL CO., LTD. (JP) 2010-07-01 US disclosed
EP-1944301-A1 NOVEL BENZOXATHIIN DERIVATIVE BANYU PHARMACEUTICAL CO., LTD. (JP) 2008-07-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100168156-A1 Novel Benzoxathiine Derivative XDH, GPR119, BRIX1 ADORA2A 2000/4885ADORA1 1885/4885SMN1; SMN2 3660/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.